cytochrome c oxidase subunit 6B2Genealiases: COXVIB2 · CT59
Q-omics provides the consensus-scored COX6B2 profile across patient tissues and cancer cell-line models. COX6B2 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, COX6B2 is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, COX6B2 RNA expression shows 15,454 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, HNSC, and UVM as cancer lineages where COX6B2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for COX6B2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes COX6B2 survival associations across molecular data types. COX6B2 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible COX6B2 RNA expression–survival associations across cancer types. High COX6B2 expression shows unfavorable associations in KIRC, ACC, MESO and LUAD, but favorable associations in ESCA and SCLC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for COX6B2 RNA expression.
This table summarizes COX6B2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for COX6B2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. COX6B2 shows lower tumor expression in KICH and COAD and higher tumor expression in HNSC, LUAD, STAD and LUSC. The HNSC box plot shows higher COX6B2 RNA expression in tumor versus normal tissue (log2 FC = +0.792, t-test p < 0.001).
This table shows molecular features associated with COX6B2 in patient tissues and cancer cell lines. In patient samples, COX6B2 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, COX6B2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BREAST and PANCREAS.
